← Back to search

Denali Therapeutics Inc

DNLI · NASDAQ

Biological Product (except Diagnostic) Manufacturing

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

ESG Scores

Overall ESG
6.1
Environmental
6.4
Social
4.2
Governance
5.5

Gender Diversity

Female Directors0.2727%
Female Executives0.3%
CEO GenderMale